UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038161
Receipt number R000043491
Scientific Title Effect of Daily Ingestion of the Test Drink on Improving Blood Lipids: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study
Date of disclosure of the study information 2019/09/30
Last modified on 2021/04/15 13:47:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Daily Ingestion of the Test Drink on Improving Blood Lipids: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study

Acronym

Beneficial Effects of the Test Drink on Improving Blood Lipids

Scientific Title

Effect of Daily Ingestion of the Test Drink on Improving Blood Lipids: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study

Scientific Title:Acronym

Beneficial Effects of the Test Drink on Improving Blood Lipids

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To prove clinical benefits and safety associated with 12 weeks daily ingestion of the test drink on improving blood lipids, in a double-blind, placebo-controlled, parallel group comparison study.
To estimate the effect of the test drink on lifestyle disease and stress.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

HDL-C at 4, 8 and 12 weeks after beginning the ingestion of test food.

Key secondary outcomes

Electroencephalogram during sleeping, sleeping record, heart rate variability, gut flora, serum carotenoid, questionnaire about subjects' background information.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Daily ingestion 160 g of juice containing active ingredients for 12 weeks.

Interventions/Control_2

Daily ingestion 160 g of juice not containing active ingredients for 12 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1.Subjects who agree to participate in this study with a written informed consent.
2.Subjects whose HDL-C is >=40 mg/dl and <60 mg/dl.

Key exclusion criteria

1.Subjects who are under physician's advice, treatment, and/or medication for dyslipidemia and/or diabetes.
2.Subjects with familial hypercholesterolemia.
3.Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
4.Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
5.Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
6.Subjects with severe anemia.
7.Pre- or post-menopausal women complaining of obvious physical changes.
8.Subjects who are at risk of having allergic reactions to drugs or foods especially based on test food, Japanese cedar, Japanese cypress, or grass.
9.Subjects who regularly take medicine, functional foods, and/or supplements which would affect blood lipid levels.
10.Subjects who regularly take foods containing ingredients of test food.
11.Heavy smokers, alcohol addicts or subjects with disordered lifestyle.
12.Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the current study.
13.Pregnant or lactating women or women who expect to be pregnant during this study.
14.Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study.
15.Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.

Target sample size

24


Research contact person

Name of lead principal investigator

1st name Jun
Middle name
Last name NISHIHIRA

Organization

Hokkaido Information University

Division name

Department of Medical Management and Informatics

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4411

Email

nishihira@do-johodai.ac.jp


Public contact

Name of contact person

1st name Jun
Middle name
Last name NISHIHIRA

Organization

Hokkaido Information University

Division name

Health Information Science Center

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Homepage URL


Email

nishihira@do-johodai.ac.jp


Sponsor or person

Institute

Hokkaido Information University

Institute

Department

Personal name



Funding Source

Organization

National Agriculture and Food Research Organization

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Bioresource and Bioenvironment Kyushu University

Name of secondary funder(s)

KAGOME CO., LTD.


IRB Contact (For public release)

Organization

The ethics committee of Hokkaido Information University

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

Tel

011-385-4411

Email

soumu@do-johodai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道情報大学 保健センター(北海道)


Other administrative information

Date of disclosure of the study information

2019 Year 09 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 09 Month 03 Day

Date of IRB

2019 Year 08 Month 27 Day

Anticipated trial start date

2019 Year 10 Month 31 Day

Last follow-up date

2020 Year 02 Month 19 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 09 Month 30 Day

Last modified on

2021 Year 04 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043491


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name